Apogee Therapeutics Future Growth
Future criteria checks 0/6
Apogee Therapeutics's earnings are forecast to decline at 24.5% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to decline by 12.6% per annum.
Key information
-24.5%
Earnings growth rate
-12.6%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 82.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 31 May 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -283 | -165 | -175 | 5 |
12/31/2025 | N/A | -201 | -149 | -131 | 6 |
12/31/2024 | N/A | -150 | -129 | -122 | 6 |
3/31/2024 | N/A | -104 | -96 | -96 | N/A |
12/31/2023 | N/A | -84 | -75 | -75 | N/A |
9/30/2023 | N/A | -70 | -56 | -56 | N/A |
6/30/2023 | N/A | -69 | -43 | -43 | N/A |
3/31/2023 | N/A | -52 | -28 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APGE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APGE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APGE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APGE is forecast to have no revenue next year.
High Growth Revenue: APGE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APGE's Return on Equity is forecast to be high in 3 years time